TrialPloS one2020

The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: A translational study [ASCENT].

Stephen John Clarke et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.